The
nitrogen-containing
bisphosphonate zoledronic acid (ZOL), a potent inhibitor of
farnesyl pyrophosphate synthase, blocks the
mevalonate pathway, leading to intracellular accumulation of
isopentenyl pyrophosphate/
triphosphoric acid I-adenosin-5'-yl
ester 3-(3-methylbut-3-enyl)
ester (
IPP/ApppI)
mevalonate metabolites.
IPP/ApppI accumulation in ZOL-treated
cancer cells may be recognized by Vγ9Vδ2 T cells as
tumor phosphoantigens in vitro. However, the significance of these findings in vivo remains largely unknown. In this study, we investigated the correlation between the anticancer activities of Vγ9Vδ2 T cells and the intracellular
IPP/ApppI levels in ZOL-treated
breast cancer cells in vitro and in vivo. We found marked differences in
IPP/ApppI production among different human
breast cancer cell lines post-ZOL treatment. Coculture with purified human Vγ9Vδ2 T cells led to
IPP/ApppI-dependent near-complete killing of ZOL-treated
breast cancer cells. In ZOL-treated mice bearing subcutaneous
breast cancer xenografts, Vγ9Vδ2 T cells infiltrated and inhibited growth of
tumors that produced high
IPP/ApppI levels, but not those expressing low
IPP/ApppI levels. Moreover,
IPP/ApppI not only accumulated in
cancer cells but it was also secreted, promoting Vγ9Vδ2 T-cell chemotaxis to the
tumor. Without Vγ9Vδ2 T-cell expansion, ZOL did not inhibit
tumor growth. These findings suggest that
cancers-producing high
IPP/ApppI levels after ZOL treatment are most likely to benefit from Vγ9Vδ2 T-cell-mediated
immunotherapy.